Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Hello Aiming, Have you noticed that a lot of the recent run in cor has been on low volume? I mean days where it opens up 3-4 cents on 3000 shares in the first half hour. Then as the day goes along, volume picks up somewhat at the "new" higher level?
I mean take today, day's half over and up a nickel on 33k shares. Try selling 33k shares and see what happens.
My level II shows very light bids on cor, people willing pay less than the current ask.
100 at .94
200 at .93
1000 at .92
600 at .90
100 at .88
100 at .84
10000 at .78 FINALLY some volume.
Not exactly a strong signal imo, and I mention it in case you want to think about selling small lots into this "strength" of late. Of course you would have to be willing to let go of perceived potential profits should RD turn out well. Most deals take time.
Anyway, just a thought if you are sitting on profits.
OT, to the poster asking me about trading cor: thanks, I trade just about anything. I try to pick up bio's when they have been hit, or slowly oversold, and I like them. I have a soft spot for cor, (see my first ihub post.) My largest position right now is dug, a bet on falling oil, at 26.11.
Take Care.
nice move in dug last week or so surf, nice call.
take care.
pretty good volume going into the close today.
back in dug, seems to bounce off the 26 and change range.
take care.
Thanks Surf, I loaded up pretty good in the .42-.45 range for a trade.
Do you have an upside in mind?
Take Care.
Morning Surf, I am showing PGLA up 55% to 1.86 in the pre-market on 7500 shares. I can't find any news.
I was wondering if you show same, or if I am just getting a bad quote.
Thanks.
Hello Food, Can't speak for anyone else here, but COR has been good to me again this year, so the melting pot of losers may may not be the best choice of words and may not apply to everyone on this board as usually I am not alone. Not bragging, just fact.
Exact highs and lows, no, but profitable, yes very. 16-50% early this year on a large, for me, number of shares, and near 80% this last go around, (once posted it was a near double, but 80% was closer,) although on much lower volume.
Best of luck to you.
Well done tregaron, "That said, we are all creatures of habit."
In my mind it goes a step further, something like "we are all creatures of habit driven by our emotions."
When the herd is buying, I like to be selling, and when the herd is selling, or have sold out, I like to be buying.
In trading, it works pretty well for me, unless my emotions get the best of me yet again
The hard part is of course in the selling, buying is easy. My emotions have to allow me to sell, knowing that I could be wrong, (oh no!,) and the stock could rocket. I have to put my perfectionism aside, and take the profits put before me, or the losses, if I bought to soon.
Take Care.
Hello Gfp, I sent you a 3 month gift to Ihub many weeks ago. It is active as I see you have the dollar sign symbol next to your name. I just assumed that Ihub would have let you know that you received it. If you click on your name it will show your current membership type is a Premium Membership.
Take Care.
Added some nuvo today, not buying much lately, but this one seems oversold to me.
Take Care.
Hello surf, I have some VNDA from lower levels that I have been holding. Are you still trading this one?
Take Care.
Hey Aiming, Actually I was talking about a delayed reaction that took days for investors to react. Cor is holding up pretty well, and now is up 2 cents on my level II.
I think most of us would agree that delays are not usually considered positive, investors get nervous and dump the stock.
Not happening here, at least yet, or I would have grabbed some this morning. Dew mentioned that in phase II this kind of thing happens, adding people to the trail that is.
Take Care.
Thanks surf, saw that on your hotbio board and saved it as a favorite for when i have time to go back and check some out.
thanks again and take care.
I was hoping to get some cor on the cheap this morning Aiming.
Sometimes there can be a delayed reaction to these things as bpax was recently to the upside, but cor may very well blow it off as a non-event.
Take Care.
Thanks Dew, It all seems jumbled to me, (but my brother would likely understand
Take Care.
Took some profits this morning, still long 25% in case more news at conference.
Thanks for assisting with this board surf.
Take Care.
Panacos Announces Results of Bevirimat Prospective Study, which Confirm Patient Response Predictors
Tuesday June 17, 4:00 pm ET
Completed Phase 2b Extension Study Determines Likely Phase 3 Patient Profile
http://biz.yahoo.com/bw/080617/20080617006463.html?.v=1
WATERTOWN, Mass.--(BUSINESS WIRE)--Panacos Pharmaceuticals, Inc. (NASDAQ: PANC - News) today announced the completion of a Phase 2b prospective study of bevirimat in treatment-experienced and treatment-naïve patients that confirms the recently discovered factors that predict response to bevirimat, its lead HIV maturation inhibitor. With 14 days of bevirimat treatment, patients with the predictors of response had a statistically significant higher mean viral load reduction than patients with polymorphisms (variants) at Gag amino acid positions 369, 370 or 371.
ADVERTISEMENT
Treatment-experienced patients who had the predictors of response had a mean viral load reduction of -1.10 log10 copies/mL with individual responses up to -2.03 log10 copies/mL. In contrast, treatment-experienced patients whose virus had the polymorphisms (variants) at Gag amino acid positions 369, 370 or 371 had a mean viral load reduction of -0.65 log10 copies/mL. In the group of treatment-naïve patients, which was not subdivided by patients with the response predictors and those without the predictors, the mean viral load reduction overall was -1.04 log10 copies/mL. For those treatment-naïve patients with the response predictors, the mean viral load reduction was -1.16 log10 copies/mL.
All patients achieved the target blood level required for optimal response with the 300mg bevirimat dose administered. Clinically, bevirimat’s adverse event profile in the prospective study was unchanged from earlier studies, where it was indistinguishable from placebo.
“In a very short period of time, we have discovered and prospectively confirmed the patient response predictors of bevirimat,” said Dr. Alan W. Dunton, Panacos’ President and CEO. “We can target the specific patients who will respond well to bevirimat in advance of treatment with a simple and rapid genotype assay, the type of HIV resistance test most frequently ordered by HIV-treating clinicians. In the population with the response predictors, we have seen a significant response to bevirimat treatment. Bevirimat’s safety profile and predictable potent response also suggest its potential utility in earlier treatment lines. I am pleased with the significant progress our team has made since our March 2008 announcement of the retrospective observation of response predictors to bevirimat.”
The predictors of response to bevirimat are located at three codon positions on the 500-amino acid HIV-1 Gag protein. Bevirimat specifically blocks a late step in processing of Gag, leading to the production of virus particles that are structurally defective and are incapable of spreading infection around the body. Patients who have virus with the most commonly occurring amino acids at positions 369, 370 or 371 on Gag (i.e., who lack polymorphisms at these positions) are much more likely to respond to bevirimat treatment. In contrast, those patients whose virus has polymorphisms (variants) at these positions are less likely to respond to the drug.
The prospective study, an extension of Study 203, was a 14-day trial in 27 treatment-experienced and treatment-naïve patients and was conducted at multiple sites in the U.S. One dose was tested in all participants: 300mg of bevirimat liquid given once a day. Patients were screened at baseline for any Gag polymorphism at positions 369, 370 or 371 and divided into 3 cohorts – 9 treatment-naïve patients, 10 treatment-experienced patients without polymorphisms and 8 treatment-experienced patients with polymorphisms. All treatment-related adverse events observed were of mild intensity. The primary endpoint was viral load reduction at day 15.
Table: Prospective Study Week 2 Viral Load Reduction (VLR) data
Patients with
Response Predictors
Patients without
Response Predictors
Significance
(No Polymorphisms at
Gag codons 369, 370
or 371)
(Any Polymorphism at
Gag codons 369, 370
or 371)
N 18 9 --
Mean Viral Load Reduction (log copies/mL) -1.13 -0.59 p < 0.04
The frequency of Gag polymorphisms is variable, depending on the population tested. In one survey of an academic patient database in North America, no polymorphisms at Gag positions 369, 370 or 371 were observed in 60.2% of 567 treatment-naïve patients nor in 59.7% of 114 treatment-experienced patients. A 2007 publication from multiple HIV clinics in France demonstrated approximately 68.3% of samples from 82 protease inhibitor-experienced patients were free of these same Gag polymorphisms (Malet, et al, AIDS 2007, Vol 21, No 7:871-3). Pending regulatory concurrence, the Company believes that patients without these Gag polymorphisms should be ideal candidates for a Phase 3 bevirimat clinical study, as they would be expected to have an optimal treatment response.
Panacos’ Development Programs
Panacos’ lead compound, bevirimat (PA-457), is the first in the new class of HIV drugs under development called maturation inhibitors, discovered by Company scientists and their academic collaborators. Bevirimat is designed to have potent activity against a broad range of HIV strains, and studies have shown bevirimat is a potent inhibitor of HIV isolates that are resistant to currently approved drugs. Panacos has completed 12 clinical studies with bevirimat in over 500 patients and healthy volunteers, showing significant reductions in viral load in HIV-infected patients and a promising safety profile. It is currently in Phase 2b clinical trials. The Company has completed a Phase 2b dose escalation study of bevirimat (Study 203) and determined the optimal dose range. The retrospective clinical data from Study 203 resulted in the discovery of the patient response predictors to bevirimat, which now has been confirmed in multiple laboratory analyses and the prospective study.
In addition to bevirimat, the Company has a second-generation program in HIV maturation inhibition and has selected a lead compound for preclinical development in its oral HIV fusion inhibitor program. The new understanding of the role of Gag polymorphisms in maturation inhibitor activity is unique to Panacos and the Company is building a strong intellectual property position around its important discovery.
About Panacos
Panacos is developing the next generation of anti-infective products through discovery and development of small molecule oral drugs for the treatment of HIV and other major human viral diseases. Approximately 1 million people in the United States and approximately 33 million people worldwide are living with HIV. Approximately 475,000 patients are treated annually for HIV in the United States. Resistance to currently available drugs is one of the most pressing problems in HIV therapy and the leading cause of treatment failure. Panacos' proprietary discovery technologies are designed to combat resistance by focusing on novel targets in the virus life cycle, including virus maturation and virus fusion.
Except for the historical information contained herein, statements made herein, including those relating to bevirimat's clinical development, the potential results of treatment with bevirimat and future clinical trials and clinical practice are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements involve risks as set forth in the Company's filings with the Securities and Exchange Commission, including, but not limited to, the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2007. These risks and uncertainties could cause actual results to differ materially from any forward-looking statements made herein. The Company undertakes no obligation to publicly update forward-looking statements, whether because of new information, future events or otherwise, except as required by applicable law.
Contact:
Panacos Pharmaceuticals, Inc.
Jane Pritchett Henderson, Chief Financial
and Business Officer, 617-926-1551
--------------------------------------------------------------------------------
Source: Panacos Pharmaceuticals, Inc.
Thanks for the heads up surf, I am long a good bit on this one.
Do you have an upside target in mind should it follow through with some volume?
Take Care.
Does anyone here follow the Canadian Market much?
I only ask because I don't keep up with it anymore, but would be very interested if an IPO comes out for the spin-off company, "Neurochemical Modulation."
Cortex's early days were great for trading, and an unknown, to most of the world, new company, might also be a great a place to put some trading dollars.
The shares out would be relatively small, guessing the float would be much less, and any decent news/pr might rocket the stock.
The added bonus would be that the Canadian Exchanges used to make Cortex's current ups and downs, look, well, placid.
Hello Surf, Any interest in NUVO at these lower levels?
I have not bitten yet, but thinking about it.
It just jumped up several cents at the close, maybe I should have jumped in and asked questions later Oh, that's right, I just did that last week with MEMY.... ugg.
Take Care.
Thanks Surf, I added a bit yesterday near the close at .38 after missing Mondays crunch. Missed today's action as well.
Take Care
i just picked some up as well.
take care.
does this sell off seem a little overblown to you?
thinking about jumping in.
take care.
likely why my orders are being gobbled up like water in the desert, without moving the bid/ask.
take care.
Hello Surf, Have you gotten back into this one yet?
I have started a position, adding a little here and there.
Take Care.
Thanks surf, I sold my heph yesterday as well. I didn't have long position, just small trading position.
Thanks again.
Hello Neuroinv, I was wondering what your take is on the possibility that R&R wants to smooth things over with Cor, in order to get the next financing? (assuming no deal in time, which is my current thinking.)
Have you seen this scenario before? Where R&R trashes a company, comes out with price targets that don't make sense, as you proved in one of your outstanding posts, then reassesses, then actually gets the next round of financing business?
Take Care.
Thanks surf for keeping me updated while i have this outdoor project going on.
I got back into panc, not long after i sold it this last time around, so it is nice to see it getting some attention.
thanks again and take care.
12:14 est 24,800 at .83
12:15 next trade 100 at .9399
talk about mm's NOT keeping a balanced marketplace.
trade smart, USE LIMIT ORDERS
Gotta love this bio rally in heph, and many others this week.
Took some cor profits this morning.
How do you like heph in here?
Take Care.
I lightened up a little this morning for a near double from just the last few weeks. (so likely it will keep going up as I am not good at picking tops historically.)
Still long some, but I didn't like that wide spread.
Take Care. BOL..
it went 1.18, next trade 1.08, then 1.07, then 1.15,
moral, USE LIMIT ORDERS
Hello asuhowe, What happened to 1.99???? kidding.
Actually, I was wondering if anyone had been selling into this rise, and if so, how did the stock react?
I haven't sold any of late, but last time I was selling, the shares were just gobbled up into obvious strength. The stock continued on an upward trend of + 30% or so from there if memory serves.... I mean 5000 shares blocks were just eaten, boom boom boom, and never even showed on level II, the orders were filled so fast, and the bid price never moved, or went up shortly after.
Sometimes selling even small amounts of cor can drive the price downward, so I am wondering how she is holding up this time around??????
take care.
Looks like folks liked what they heard in the call.
Take Care.
Slightly OT- FDA environment.
I found this while researching another stock. It talks a little about the current FDA environment with respect to sleep drugs. I put in bold what I found interesting and wondered if it translates into other areas of FDA scrutiny.
"Next, just a couple of thoughts on the regulatory environment. While we all operate in an environment of increased scrutiny by the FDA, we believe, based upon statements by representatives of the agency that the regulatory requirements for insomnia agents have not changed. That is, for the broad primary market, you must successfully complete two pivotal studies in insomniacs and two in the elderly.
There's been some confusion on this issue since last December, when another sponsor received an approvable letter on their insomnia application. Specifically, there have been questions around whether the FDA will, as a general rule, require additional large studies such as comparative safety studies for approval.
As many of you are aware, Russ Katz, head of the Neuropharm division of FDA, spoke at the Sleep Research Society's Sleep Course in New York on April 3 of this year. At this meeting, Dr. Katz communicated two things that are particularly noteworthy. First, he confirmed that the regulatory requirements for sleep drugs have not changed, noting that any issues encountered by specific drugs under review are unique to that drug. Second, Dr. Katz indicated that the FDA has a heightened interest in patient-reported outcomes, an area where adipiplon has shown very robust results."
http://seekingalpha.com/article/79538-neurogen-corporation-q1-2008-earnings-call-transcript?source=yahoo
I think it is more likely "The Economist" article that came out Thursday. Pretty well respected paper. Newbies might think they have the next big thing and are tossing a few dollars cor's way.
jmo.
Take Care.
Thanks surf, I am heading out, and am also temped to get back in, but resisting. May put in order at .45-.47 or so just in case they really get scarred and sell it off.
Added a little more nrgn....
Take care and thanks again.
Hello gfp, I thought you had sent me a pm, you can do that now:-, and when I went to answer it, it was gone. (realized it was cor post.)
Mostly bio now, including a little cor. not many cor dollars now.....
played some dug, short term oil etf, it bets on falling oil, made money twice, then lost money several times as I stopped myself out around a dollar under what I got it for. thank goodness.
just missed zmh options again as I was busy with pool project here at the house. zmh falls to the mid 60 dollar range, and i will buy options every time.....duration varies with what's up with company and how long i think it will take to recover. it is kind of like cor in my mind, in that it always seems to come back
I appreciate you cor posts. Thanks.
heading out the door......
--I had even added Memory as a recommendation, with the usual profound effect.--
Nice call on memy neuroinv. I was in because of a 1 MILLION share insider purchase at .55 back in Nov., and the price kept falling, so I got in. It was stunning, and a little gut wrenching, to see it not move on the recent news. Granted not many insiders have that kind of money laying around, but it is good to see cor insiders stepping up. I am out of memy as of today, for now.
I think there might be a lesson for COR longs, (talking to myself here,) should RD prove out, but the stock not move much, or for long, initially. At least there a possibility for a head fake and then a spike on good RD. But you have to sell the spikes in this sector, imo, or get really lucky.
I have nibbled a little at cor in the 60's, not much, but just in case the RD goes well, and my radar is off, and it pops big. That's a scenario I just don't think will happen, (the big pop,) but I am wrong so often that I wanted to be in a little more than my IRA's.
Thanks for your contributions to the cor board.
---there is a memy board up on ihub that would love to hear your thoughts for the future should you find time, energy, and desire to post----
I agreed on the "run" running out of steam and sold off more in the mid 80's. I think I averaged out around .79 today thanks to your post!
Got a little of nrgn this am as well, thanks for the heads up.
Take Care.
Thanks Surf, looks like you were holding it back and I guess there was some more upside bottled up that let itself loose this morning...
I lightened up some this morning and took some profits.
Just couldn't get past that 1 million share insider buy a while back.....which I wouldn't have even known about had you not posted so here.....
Thanks again.